Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
Clinical trial NCT01506271 · COMPLETED
Trial details
- NCT number
- NCT01506271
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-06-01
- Primary completion
- 2014-08-12
- Enrollment
- 351
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.